ISSN:
1435-5604
Keywords:
Ipriflavone
;
Osteoporosis
;
Bone mass
;
Single-photon absorptiometry
;
Dual-energy x-ray absorptiometry
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Ipriflavone (IP) 600 mg/day was administered for 1 year to osteoporotic females either as a single continuous daily dose or as the depressor component of activate-depress-free-repeat (ADFR) therapy. The effects of IP, an inhibitor of bone resorption, on bone mass density (BMD) were examined. Studies of both groups, the single-dose regimen group and the ADFR therapy group, revealed not only that the BMD was maintained, but that it actually increased in the metaphysis of the radius when measured using single-photon absorptiometry. In the group administered IP as a single-dose regimen, 36.4% of the subjects showed an increase of more than 3% in BMD. In the ADFR group, using IP as the depressor, 45.5% showed an increase of more than 3% in the BMD of the metaphysis of the radius. In the control group using lactocalcium as a placebo, 14.3% of the patients showed an increase of more than 3% in the BMD of the metaphysis of the radius. IP effectively increased BMD in the early stages of bone loss. Measurements of BMD of the lumbar vertebrae (L2–L4), however, showed no significant differences between the control group and the two groups receiving IP.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02378745
Permalink